

BelHealth Investment Partners Acquires Apothecary by Design

** Leading specialty pharmacy targeting women's health*

New York, NY – August 17, 2015 – BelHealth Investment Partners (“BelHealth”), a healthcare-focused private equity firm, announced the acquisition of Apothecary by Design (“ABD” or the “Company”).

Founded in 2008 and headquartered in Portland, Maine, ABD is a specialty pharmacy focused on women's health, hepatitis C and autoimmune disorders. ABD services fertility patients nationally and other patients throughout the Northeast. The Company maintains deep relationships with patients, physicians, payors and manufacturers.

Nathan Kronforst, BelHealth Managing Director, stated, “Given BelHealth's prior experience in the specialty pharmacy sector through our investments in Aureus and Linden Care, we can leverage our industry knowledge and relationships to build another successful national platform in the sector. ABD is well positioned in the fragmented fertility segment of the pharmacy market and we look forward to establishing the Company as the pre-eminent specialty pharmacy in the U.S. specializing in women's health.”

Harold S. Blue, BelHealth Managing Partner, stated, “We are excited to partner with the founders of ABD to help them penetrate new markets and strengthen their already impressive business. The Company has established a strong presence within their geographic community and we look forward to working with the Company and founders to continue to expand our footprint nationally. We plan to expand the current team and surround them with other experienced industry executives. BelHealth's strategic plan will focus on organic growth and the aggressive pursuit of add-on acquisitions.”

About BelHealth Investment Partners

BelHealth Investment Partners (“BelHealth”), based in New York, is a healthcare private equity firm focused on lower middle market companies. BelHealth has a unique combination of investing, executive management and entrepreneurial experience. BelHealth acquires majority positions in entrepreneur-owned companies that it believes would benefit from its extensive operating and private equity investment expertise. The firm typically invests \$20-40 million per platform company across three healthcare segments: Services, Products and Distribution.

For further information, please visit:

Apothecary by Design: www.apothecarybydesign.com

BelHealth Investment Partners: www.belhealth.com

Contact:

Apothecary by Design: Mark McAuliffe (207) 899-0663

BelHealth Investment Partners: Inder Tallur (347) 308-7018